Sanofi's Breakthrough Hemophilia Treatment Gains FDA Approval

Sanofi's Breakthrough Hemophilia Treatment Gains FDA Approval
2 months ago

In a significant advancement for hemophilia treatment, Sanofi has announced that the U.S. Food and Drug Administration (FDA) has granted approval for its latest drug designed to manage this genetic disorder. The new medication, touted for its improved ease of use, aims to enhance the quality of life for individuals suffering from hemophilia, a condition characterized by the inadequate clotting of blood due to the absence of certain proteins.

Continue reading
Sangamo Therapeutics Faces Deplorable Stock Plunge Following Pfizer's Withdrawal from Hemophilia Treatment Deal

Sangamo Therapeutics Faces Deplorable Stock Plunge Following Pfizer's Withdrawal from Hemophilia Treatment Deal
5 months ago

Sangamo Therapeutics, a company specializing in gene therapy and related innovations, witnessed a catastrophic decline in its stock value after pharmaceutical giant Pfizer decided to terminate their partnership regarding a hemophilia treatment. This abrupt end to the collaboration has sent shockwaves through the markets and raised numerous questions about the future capabilities and financial health of Sangamo.

Continue reading